Black Pearl SA
0.25
PLN
-0.01
(-3.08%)
ISIN
PLBLKPC00014
Return %
Stock
S&P 500
1Y
82.61
14.20
3Y
36.22
81.12
5Y
-63.48
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Rafal Kmiecik
- Sector
- Finance
- Industry
- Investment banks/Brokers
- Address
- Warsaw Poland
- IPO Date
- Mar 31, 2010
- Website
- blackpearlcapital.pl
- Similar Companies
- Business
- Black Pearl S.A. is an investment holding company that specializes in private equity, venture capital, and strategic management for small and medium-sized enterprises across the biopharmaceutical, healthcare, cannabis, and real estate sectors. The company operates through several dedicated business segments and portfolio entities, providing equity and debt capital investments for early-stage and expanding enterprises; corporate advisory, asset restructuring, and strategic management services; real estate development and property investment projects via entities including ECO MILAN Sp. z o.o.; the research, manufacture, and commercial distribution of certified medical devices, over-the-counter pharmaceuticals, dietary supplements, and specialized dermatological cosmetics through Red Pharma Laboratories Polska S.A., featuring specialized skincare product lines such as the DERMO series formulated for atopic dermatitis, eczema, and psoriasis; and investment management, project financing, and product distribution in the legal medical cannabis and phytopharmaceutical industries through CANNABISHUBMED Sp. z o.o. and MEDICANCOIN GREECE S.A. Black Pearl S.A. serves retail consumers, healthcare providers, pharmacies, and commercial partners across Poland, Greece, and the broader European market. Founded in December 2009 and publicly listed on the NewConnect market of the Warsaw Stock Exchange, the company is headquartered in Warsaw, Poland. In recent major corporate developments, Black Pearl S.A. has executed strategic operational expansions and capital structure reorganizations, including securing an official regulatory extension through 2030 for the MEDICANCOIN GREECE S.A. production and processing facility project in the Corinth region of Greece; restructuring its debt obligations through an extension of the maturity period for its series P corporate bonds from 24 to 36 months; pivoting its primary investment strategy toward the biopharmaceutical, medicinal cannabis, and specialized consumer health sectors; and consolidating its governing ownership structure following substantial equity position adjustments by principal shareholder Janusz Skopowski to support ongoing cross-border project execution and portfolio development.